‹ ARQT latest research

ARQT (Arcutis Biotherapeutics, Inc.): every AI call and what happened next

TradeFlare's AI research teams analysed ARQT on 7 market nights between August 3, 2026 and September 23, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.

7 calls 5 BUY · 2 HOLD · 0 SELL BUY calls up after 20 trading days: 0 of 5
DateVerdictPriceTarget / stop5 days later20 days laterWhy (that night)
September 23, 2026 HOLD $27.78 $32.80 / $23.61 +0.2% not yet
The stock is showing signs of consolidation after a recent gap up, and the technicals are leaning bearish, suggesting a short-term holding pattern.
August 12, 2026 BUY $26.23 $30.12 / $22.27 +0.7% -11.0%
The post-earnings drift signal suggests momentum may continue over the coming weeks.
August 11, 2026 BUY $25.29 $29.94 / $21.49 +1.2% -9.1%
The post-earnings drift signal suggests a sustained upward move over several weeks.
August 10, 2026 BUY $25.29 $29.94 / $21.49 -1.2% -5.9%
The post-earnings drift signal suggests a sustained upward move over several weeks.
August 5, 2026 BUY $26.03 $30.72 / $21.76 -3.0% -12.0%
The current market regime supports opportunistic trades with wider TP targets, and the fundamental and sentiment analyses suggest a bullish outlook that may take time to fully materialize.
August 4, 2026 HOLD $25.94 — / — +0.8% -8.8%
Continued strong revenue growth driven by ZORYVE.
August 3, 2026 BUY $26.86 $30.89 / $22.83 -0.1% -7.6%
The technical setup suggests a short-term bounce opportunity, while the fundamental and sentiment factors point to longer-term upside potential.

Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.